Terns Pharmaceuticals, Inc. TERN
Set alert
At close · May 15
After hours · May 15, 4:00 PM ET
- YTD
- +31.06%
- 1 year
- +1,797.85%
- Open
- 52.97
- Prev close
- 52.95
- Mkt cap
- 6.12B
- Vol
- 6.33M
- Avg vol
- 4.84M
- EPS
- -1.03
- P/E
- -68.77
- Div yield
- 0.00%
More statistics
- Low
- 52.95
- High
- 52.97
- Beta
- -0.38
- Inst. own
- 109.69%
- Dividend
- 0.00
Key statistics
- Market cap
- 6.12B
- Enterprise value
- 5.59B
- Trailing P/E
- -68.77
- PEG ratio
- -7.37
- Price / sales
- 0.00
- Price / book
- 4.90
- Beta
- -0.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -13.59%
Analyst view
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.26333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 14, 2026 | Mar 31, 2026 | -0.30 | -0.26 | +0.04 | +13.33% |
| Mar 30, 2026 | Dec 31, 2025 | -0.29 | -0.25 | +0.04 | +13.79% |
| Nov 10, 2025 | Sep 30, 2025 | -0.30 | -0.27 | +0.03 | +10.00% |
| Aug 5, 2025 | Jun 30, 2025 | -0.28 | -0.26 | +0.02 | +7.14% |
| May 8, 2025 | Mar 31, 2025 | -0.29 | -0.26 | +0.03 | +10.34% |
| Mar 20, 2025 | Dec 31, 2024 | -0.30 | -0.24 | +0.06 | +20.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | down | Outperform | Perform |
| Apr 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Mar 31, 2026 | Truist Securities | down | Buy | Hold |
| Mar 30, 2026 | Barclays | down | Overweight | Equal-Weight |
| Mar 26, 2026 | Citizens | down | Market Outperform | Market Perform |
| Mar 26, 2026 | TD Cowen | down | Buy | Hold |
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 59
- Website
- ternspharma.com
News
- Tern shares surge as it ups stakes in AI health services company Talking Medicines
- 'Merck Starts Seven-Part High-Grade Bond Sale to Fund Terns Deal' - Bloomberg
- Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
- Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
- Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
- Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
- Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
- Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Your note
Sign in to keep a note on TERN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURROUGHS AMY LOUISE | Chief Executive Officer | Sale | Mar 15, 2026 | 297,295 |
| GENGOS ANDREW | Chief Financial Officer | Stock Award(Grant) | Jan 13, 2026 | 101,788 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 15, 2024 | 0 |
| KURIAKOSE EMIL T. | Officer | Sale | Mar 31, 2026 | 105,673 |
| LU HONGBO B | Director | Purchase | Sep 11, 2024 | 0 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 15, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.09% | 8,194,218 | 433.88M | Dec 30, 2025 |
| Morgan Stanley | 6.88% | 7,945,608 | 420.72M | Dec 30, 2025 |
| Adage Capital Partners GP L.L.C. | 4.80% | 5,550,000 | 293.87M | Dec 30, 2025 |
| Vanguard Group Inc | 4.78% | 5,523,948 | 292.49M | Dec 30, 2025 |
| Vivo Capital, LLC | 4.63% | 5,346,928 | 283.12M | Dec 30, 2025 |
| Vestal Point Capital, LP | 3.90% | 4,500,000 | 238.28M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.76% | 3,184,983 | 168.64M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.01% | 2,320,931 | 122.89M | Mar 30, 2026 |
| LORD ABBETT SECURITIES TRUST-Lord Abbett Growth Leaders Fund | 1.38% | 1,588,735 | 84.12M | Jan 30, 2026 |
| SmallCap World Fund Inc | 0.92% | 1,060,000 | 56.13M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.80% | 927,850 | 49.13M | Dec 30, 2025 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.73% | 839,458 | 44.45M | Feb 27, 2026 |